Biosimilars slated for 12 years market exclusivity

Share this article:
In a move applauded by brand name manufacturers, the Senate Health, Education, Labor and Pensions Committee and its House counterpart voted in July to support 12 years market exclusivity for biologic innovators under a follow-on biologics (biosimilars) provision attached to its healthcare reform bill.

It now awaits passage in each chamber, reconciliation in a conference and final votes after the August recess.
“The language approved … strikes the appropriate balance among ensuring patient safety, expanding competition, reducing costs and providing necessary and fair incentives that will provide for continued biomedical breakthroughs,” said Biotechnology Industry Organization president Jim Greenwood.

Both committers had “embraced our long-held belief that a minimum of 12 years of data exclusivity establishes a fair and reasonable period to ensure continued biomedical innovation and provide the benefits of competition,” he said. 

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Headliner: Ipsen head leads continental charge

Headliner: Ipsen head leads continental charge

"When I look at the business, I actually see patients in my mind. I don't see numbers."

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets